Source: Virtual Congress 2020 – Management issues in thoracic oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
F. Leoncini (Brescia, Italy), G. Levi (Brescia, Italy), M. Novali (Brescia, Italy), F. Quadri (Brescia, Italy), E. Martinelli (Brescia, Italy), M. Bezzi (Brescia, Italy). Does a MultiDisciplinary Team approach affect time to treatment in NSCLC?. 2914

Member's Comments

No comment yet.

Related content which might interest you: Managing patient pathways to achieve lung cancer waiting time targets: Mixed method study Source: Annual Congress 2011 - How to improve lung cancer care Year: 2011 Pushing the limits, real benefit for the patient ? – a curative treatment approach in an unfit lung cancer patient Source: International Congress 2017 – GR2 Lung Cancer Grand Round Year: 2017 Nurse led lung cancer diagnostic/supportive follow up clinic;a different approach to optimise lung cancer pathway Source: International Congress 2018 – The many facets of respiratory nursing Year: 2018 Reducing delays in lung cancer diagnostic pathways to improve patient experience Source: International Congress 2016 – Quality management and quality of life in lung cancer Year: 2016 Does a straight-to-CT pathway improve lung cancer patient waiting times? Source: Annual Congress 2008 - Treatment of thoracic tumours Year: 2008 The rate of curative intended therapy against recurrent lung cancer before and after introduction of a CT-based follow-up program Source: Annual Congress 2013 –Quality management in thoracic oncology Year: 2013 Panel discussion: Improving the pathway of lung cancer patients, can we do it better? Source: ERS webinar 2021: Panel discussion on improving the pathway of lung cancer patients, can we do it better? Year: 2021 Can we expect progress from targeted therapy of SCLC? Source: Eur Respir Monogr 2015; 68: 234-246 Year: 2015 Is time from "referral to diagnosis" in lung cancer pathway affected by diagnostic test delays? Source: International Congress 2015 – Quality management in lung cancer Year: 2015 Symptom control in advanced non-small cell lung cancer (NSCLC): what is the influence of cisplatin-use, age, performance status and duration of chemotherapy? Analysis of a randomized database Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002 Impact of early weight loss during concurrent chemoradiotherapy on survival in advanced stage NSCLC patients Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Diagnostic delay time of lung cancer in a community study Source: Annual Congress 2008 - Various aspects of thoracic oncology Year: 2008 Novel survey tool used to assess priorities of lung cancer patients and carers Source: International Congress 2015 – Quality management in lung cancer Year: 2015 Targeted therapies for lung cancer: how did the game begin? Source: Breathe 2016; 12: 177-179 Year: 2016 Approaches in patients with locally advanced NSCLC: a surgeon's perspective Source: Eur Respir Monogr 2015; 68: 167-177 Year: 2015 Early, locally advanced and metastasised NSCLC: core strategies from the perspective of the radiotherapist Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019